Tagworks Pharmaceuticals BV – Trademark Portfolio
Entity Type: 99
Tagworks Pharmaceuticals BV holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include TAGWORKS. The owner is based in Nijmegen.
c/o Radboud UMC, Dept. Nucl. Med. & Rad.
Nijmegen 6525GA , NL
Showing of trademarks Trademarks
Trademark Classifications
Tagworks Pharmaceuticals BV's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Tagworks Pharmaceuticals BV have?
Tagworks Pharmaceuticals BV has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Tagworks Pharmaceuticals BV file in?
Tagworks Pharmaceuticals BV files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Tagworks Pharmaceuticals BV's most well-known trademarks?
Tagworks Pharmaceuticals BV's registered trademark portfolio includes well-known marks such as TAGWORKS. These are among 1 currently registered trademark in the portfolio.
What is Tagworks Pharmaceuticals BV's trademark registration success rate?
Tagworks Pharmaceuticals BV has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.